Abstract
Insulin Resistance (IR) is a component of the pathogenesis of type 2 diabetes mellitus (T2DM), and risk factor for cardiovascular and neurodegenerative diseases. Amino acid and lipid metabolomic IR diagnostics associate with future T2DM risk in epidemiological cohorts. Whether these assays can accurately detect altered IR following treatment has not been established. In the present study we evaluated the ability of metabolomic diagnostics to predict altered IR following exercise treatment. We evaluated the performance of two distinct insulin assays and built combined clinical and metabolomic IR diagnostics. These were utilised to stratify IR status in the pre-intervention fasting samples in three independent cohorts (META-PREDICT (MP, n=179), STRRIDE-AT/RT (S-2, n=116) and STRRIDE-PD (S-PD, n=149)). Linear and Bayesian projective prediction strategies were used to evaluate biomarkers for fasting insulin and HOMA2- IR and change in fasting insulin with treatment. Both insulin assays accurately quantified international standard insulin (R2>0.99), yet agreement for fasting insulin was less congruent (R2=0.65). Only the high-sensitivity ELISA assay could identify the mean effect of treatment on fasting insulin. Clinical-metabolomic models were statistically related to fasting insulin (R2 0.33 – 0.39) but had modest capacity to classify HOMA2-IR at a clinically relevant threshold. Furthermore, no model predicted treatment responses in any cohort. Thus, we demonstrate that the choice of insulin assay is critical when quantifying the influence of life-style on fasting insulin, while none of the clinical-metabolomic biomarkers, validated in cross-sectional data, are suitable for monitoring longitudinally changes in IR status.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01920659
Funding Statement
The clinical data utilised in this study was funded by multiple sources: European Union Seventh Framework Programme (META-PREDICT, HEALTH-F2-2012-277936); STRRIDE II (NCT00275145) by NHLBI grant HL-057354 and STRRIDE-PD (NCT00962962) by NIDDK DK-081559 and R01DK081559. The data modelling was supported by Augur Precision Medicine LTD.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by local ethics committees at all sites (the University of Nottingham Medical School Ethics Committee: D8122011 BMS; the Regional Ethical Review Board Stockholm: 2012/753-31/2; the ethics committee of the municipality of Copenhagen and Frederiksberg in Denmark: H-3-2012-024; Comite etico de Investigacion Humana de la ULPGC: CEIH-2012-02; and the Loughborough University Ethics Approvals Human Participants Sub-Committee: 12/EM/0223) and complied with the 2008 Declaration of Helsinki. To ensure accurate results, we were obliged to discontinue training for individuals who: (i) failed to attend for more than 2 consecutive sessions, (ii) missed more than 3 (∼15%) training sessions in total, or (iii) failed to complete their set exercise regime on 2 occasions or more. This was not the case for any participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Senior Authors
The author order was incorrectly displayed on the original deposition
Data Availability
The clinical and metabolomic Data and the analysis script can be found at 10.5281/zenodo.13819578.
